Back to Search
LAUREN GIANNI, PHARMD
PHARMD
Pharmacist
NPI: 1962174847Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
28197(MD)
Research & Publications (20)
Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours.
PMID 19190075·Ann Oncol·2009
3-trial
Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
PMID 19332727·J Clin Oncol·2009
3-trial
Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.
PMID 19114300·Eur J Cancer·2009
3-trial
Lipoplatin monotherapy: A phase II trial of second-line treatment of metastatic non-small-cell lung cancer.
PMID 19297279·J Chemother·2009
3-trial
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.
PMID 19419856·Eur J Cancer·2009
3-trial
Never use anthracyclines with trastuzumab: it is time to reconsider the taboo.
PMID 19387827·Breast Cancer Res Treat·2009
8-other
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer.
PMID 19107109·Nat Clin Pract Oncol·2009
6-review
Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer.
PMID 19255335·J Clin Oncol·2009
6-review
Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group.
PMID 19062268·Eur J Cancer·2009
3-trial
Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours.
PMID 19239440·BJU Int·2009
8-other
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours.
PMID 18640031·Eur J Cancer·2008
3-trial
The "other" signaling of trastuzumab: antibodies are immunocompetent drugs.
PMID 18347004·J Clin Oncol·2008
8-other
Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group.
PMID 17629752·Support Care Cancer·2008
2-rct
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
PMID 18258991·J Clin Oncol·2008
6-review
p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer.
PMID 18272916·Ann Oncol·2008
4-observational
Introducing new molecular technologies into routine clinical cancer care: is there an impact on the treatment of breast cancer?
PMID 18790944·Ann Oncol·2008
8-other
Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
PMID 17652806·Cardiovasc Toxicol·2007
6-review
Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule.
PMID 17761711·Ann Oncol·2007
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1202 NATIONAL HWY
LAVALE, MD 21502 - Phone
- (301) 729-1004
Quick Facts
- NPI
- 1962174847
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile